Vardenafil (Levitra/Staxyn) Liver Function Impact

How Vardenafil Is Processed by the Liver

Vardenafil's entire therapeutic and safety profile is tied to hepatic metabolism. After oral absorption, the drug undergoes extensive first-pass metabolism in the liver, producing M1 as its primary active metabolite. M1 carries roughly 7% of the pharmacologic activity of the parent compound, and both are cleared almost completely via biliary excretion. Less than 0.001% of the dose appears unchanged in urine. That near-total hepatic dependence means liver function shapes every aspect of vardenafil exposure: peak concentration, time to peak, elimination half-life, and the drug's interaction profile with co-administered agents. FDA prescribing information for Levitra (vardenafil HCl) summarizes this metabolic pathway in detail.

CYP Enzymes Responsible for Clearance

CYP3A4 performs the majority of vardenafil oxidation, with CYP3A5 contributing a secondary but clinically meaningful share. Research published on PubMed confirms CYP3A4 as the dominant isoform responsible for vardenafil N-deethylation. CYP2C9 plays a minor role. Because CYP3A4 is the same enzyme that activates and deactivates dozens of commonly prescribed drugs, including macrolide antibiotics, azole antifungals, HIV protease inhibitors, and certain antihypertensives, the potential for clinically significant interactions in patients who also have liver disease is compounded.

First-Pass Effect and Bioavailability

Oral bioavailability of vardenafil in healthy volunteers averages 15%, reflecting substantial first-pass extraction. Fatty meals modestly delay time to peak concentration (Tmax) without meaningfully changing overall exposure. When hepatic extraction capacity falls due to cirrhosis or fibrosis, first-pass metabolism decreases and bioavailability rises accordingly, directly increasing systemic drug levels even at identical doses.

Pharmacokinetic Changes in Hepatic Impairment

The degree of liver dysfunction, classified by the Child-Pugh score, predicts vardenafil exposure with reasonable precision. Studies indexed on NCBI confirm that hepatic impairment alters PDE5 inhibitor pharmacokinetics in a grade-dependent manner. The FDA conducted dedicated pharmacokinetic studies comparing healthy controls, Child-Pugh A patients, and Child-Pugh B patients before approving current label guidance.

Child-Pugh A (Mild Impairment, Scores 5 to 6)

In patients with Child-Pugh A disease, vardenafil's area under the plasma concentration-time curve (AUC) increases by approximately 17% and maximum concentration (Cmax) rises by about 30% compared to matched healthy volunteers. These modest changes do not require a dose reduction at initiation. The standard starting dose of 10 mg remains appropriate, with titration to 20 mg or down to 5 mg based on efficacy and tolerability. The FDA label does not restrict vardenafil use in Child-Pugh A beyond the usual contraindication for severe cardiovascular disease.

Child-Pugh B (Moderate Impairment, Scores 7 to 9)

The pharmacokinetic shift becomes clinically significant in Child-Pugh B. AUC roughly doubles and Cmax increases by approximately 50% to 100% relative to healthy subjects, according to the FDA-approved Levitra label. The extended half-life, now approaching 8 to 10 hours, raises time-averaged drug levels throughout the dosing interval. The approved starting dose cap of 5 mg in Child-Pugh B reflects these findings. Physicians should also avoid titration above 5 mg unless tolerability data in the individual patient supports it.

Child-Pugh C (Severe Impairment, Scores 10 to 15)

No controlled pharmacokinetic data exist for Child-Pugh C because the safety risk was considered unacceptable for study. Drug accumulation is expected to be severe, and the risk of symptomatic hypotension, prolonged penile erection, and systemic vasodilation is unquantifiable. Vardenafil is contraindicated in this population. Clinicians should consider whether erectile dysfunction management through non-pharmacologic means or alternative mechanisms is more appropriate in patients with decompensated cirrhosis.

Vardenafil's Effect on Liver Function Tests

Alanine Aminotransferase and Aspartate Aminotransferase

Across registration trials, vardenafil did not produce statistically meaningful elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above placebo. The incidence of ALT elevation greater than three times the upper limit of normal was below 1% in both the vardenafil and placebo arms in key Phase III studies. That near-placebo rate suggests the drug is not intrinsically hepatotoxic at therapeutic doses in patients with normal or mildly impaired liver function. FDA safety data for Levitra support this conclusion.

Bilirubin and Alkaline Phosphatase

No clinically significant changes in serum bilirubin or alkaline phosphatase have been attributed to vardenafil in published clinical trial data. This absence of cholestatic signal separates it from some older drugs processed by the same enzymes. Routine liver function monitoring is not mandated during vardenafil therapy in patients without pre-existing hepatic disease, per current FDA labeling. National Library of Medicine drug interaction databases confirm the absence of a defined hepatotoxicity signal for vardenafil.

Long-Term Exposure Data

No large long-term trial has evaluated serial liver function testing in vardenafil users over periods exceeding 12 months. The absence of post-marketing signals in the FDA adverse event reporting system (FAERS) over more than two decades of use suggests a favorable hepatic safety profile in patients with intact or mildly reduced liver function. Clinicians managing patients on chronic vardenafil therapy alongside other hepatically metabolized drugs should apply standard pharmacovigilance principles rather than vardenafil-specific liver monitoring.

Drug Interactions Mediated Through Hepatic Pathways

Because CYP3A4 handles the bulk of vardenafil clearance, co-administration with CYP3A4 inhibitors produces the most clinically dangerous interaction category. The NCBI drug metabolism literature documents the degree of CYP3A4-mediated elevation in PDE5 inhibitor exposure.

Strong CYP3A4 Inhibitors

Ritonavir, a potent CYP3A4 inhibitor used in HIV regimens, raises vardenafil AUC by approximately 1,500% (15-fold). The approved label limits vardenafil to a single 2.5 mg dose no more than once every 72 hours in patients receiving ritonavir. Ketoconazole 400 mg, an azole antifungal and pharmacological CYP3A4 probe inhibitor, raises vardenafil AUC by roughly 1,000% in controlled studies. FDA interaction data in the Levitra prescribing information specify dose caps for each inhibitor tier. Clarithromycin, itraconazole, and indinavir fall into the same high-risk category.

Moderate CYP3A4 Inhibitors

Erythromycin at 500 mg three times daily raised vardenafil AUC by approximately 300% in a dedicated pharmacokinetic study. Fluconazole, verapamil, and diltiazem produce comparable exposure increases. For patients who require a moderate inhibitor and have no hepatic impairment, the label recommends a maximum vardenafil dose of 5 mg per 24 hours. When moderate inhibitor use coincides with Child-Pugh A or B disease, the interaction and impairment effects are additive, making doses above 2.5 mg potentially unsafe. NCBI pharmacokinetic resources confirm dose-dependent CYP3A4 inhibition effects on vardenafil.

CYP3A4 Inducers

Rifampin, carbamazepine, and phenytoin induce CYP3A4 and may substantially reduce vardenafil plasma levels. Patients on strong inducers may experience treatment failure at standard doses, though no formal dose-adjustment recommendation exists in the label because efficacy was not the FDA's primary concern in these studies. Published pharmacokinetic principles for CYP3A4-metabolized drugs support anticipating reduced exposure with enzyme inducers.

Alcohol and Hepatic Load

Alcohol is both a substrate and an inducer/inhibitor of hepatic enzymes depending on consumption pattern. Acute moderate alcohol intake (blood alcohol approximately 0.08%) combined with vardenafil 20 mg did not produce clinically meaningful additional blood pressure reduction beyond either agent alone in a dedicated crossover study cited in the FDA label. Chronic heavy alcohol use, however, contributes to alcoholic liver disease and thereby shifts patients into Child-Pugh classifications that directly affect dosing. CDC alcohol and liver disease statistics confirm that chronic heavy drinking is a leading cause of cirrhosis in the United States.

The Porst et al. 2003 Trial and What It Means for Metabolically Complex Patients

Porst et al. (Int J Impot Res, 2003; N=452) evaluated vardenafil in men with diabetes mellitus and erectile dysfunction, a population that frequently carries comorbid non-alcoholic fatty liver disease (NAFLD) and insulin resistance-associated hepatic dysfunction. The full trial is indexed at PubMed PMID 12834456.

Trial Design and Efficacy Findings

The study was a randomized, double-blind, placebo-controlled trial testing vardenafil 10 mg and 20 mg against placebo over 12 weeks. Diabetic men are a pharmacokinetically relevant subgroup because type 2 diabetes is associated with hepatic steatosis in 55 to 75% of patients. Despite this background hepatic burden, vardenafil produced significant improvements on the International Index of Erectile Function (IIEF) erectile function domain score. The 20 mg dose raised IIEF scores by a mean of 6.6 points versus 1.9 points for placebo (P<0.001). Successful intercourse attempts occurred in 57% of vardenafil 20 mg patients versus 28% of placebo patients.

Liver Safety Signal in the Diabetic Population

The Porst trial did not report excess hepatic enzyme elevations in the diabetic cohort compared to general population data from other Phase III trials. This finding is informative: a population enriched for fatty liver disease did not show a hepatotoxicity signal above baseline. The absence of a signal does not eliminate caution in patients with established fibrosis or cirrhosis, but it does suggest that uncomplicated hepatic steatosis without advanced fibrosis may not substantially alter vardenafil's liver safety profile.

Clinical Relevance for Today's Practice

Given the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) in men seeking ED treatment, the Porst data offer partial reassurance. Clinicians treating men with obesity, type 2 diabetes, or metabolic syndrome who also have ED should assess baseline liver function. A FIB-4 score or transient elastography result that places the patient in an advanced fibrosis or cirrhosis category changes prescribing decisions meaningfully. AASLD guidelines on NAFLD evaluation recommend FIB-4 as a first-line non-invasive fibrosis assessment.

Dosing Framework for Patients With Hepatic Disease

The table below integrates FDA label guidance with clinical pharmacokinetic principles to give prescribers a practical reference.

| Child-Pugh Class | Score Range | AUC Change vs. Healthy | Recommended Starting Dose | Max Dose | |---|---|---|---|---| | Normal (no disease) | N/A | Reference | 10 mg | 20 mg per 24 h | | A (Mild) | 5 to 6 | +17% | 10 mg | 20 mg per 24 h | | B (Moderate) | 7 to 9 | ~+100% | 5 mg | 5 mg per 24 h | | C (Severe) | 10 to 15 | Undetermined | Contraindicated | Contraindicated |

For patients on strong CYP3A4 inhibitors, these dose ceilings drop further regardless of Child-Pugh class. A patient with Child-Pugh B disease taking ritonavir has two separate pharmacokinetic reasons for extreme caution, and the co-prescription of vardenafil in that scenario should be avoided unless no alternative exists and the prescriber has cardiology input. FDA Levitra full prescribing information serves as the authoritative source for these recommendations.

Monitoring Hepatic Function During Vardenafil Therapy

Baseline Assessment

Before prescribing vardenafil to any patient with known or suspected liver disease, obtain a baseline comprehensive metabolic panel (CMP) that includes ALT, AST, alkaline phosphatase, total bilirubin, albumin, and total protein. For patients with obesity, type 2 diabetes, or heavy alcohol use, calculate a FIB-4 index (age × AST / (platelet count × square root of ALT)). A FIB-4 above 2.67 warrants gastroenterology referral before initiating therapy. NIH guidance on non-invasive liver fibrosis assessment supports FIB-4 as a validated clinical tool.

On-Therapy Monitoring Intervals

The FDA label does not mandate routine on-therapy liver function testing in patients without pre-existing liver disease. In patients with Child-Pugh A or B disease, a CMP at 3 months after initiation and then every 6 months is a reasonable interval given the absence of an intrinsic hepatotoxicity signal but the potential for disease progression to change pharmacokinetics over time. If ALT rises above three times the upper limit of normal on two separate measurements, suspending vardenafil and evaluating for other causes is appropriate. AASLD monitoring recommendations for patients with chronic liver disease and co-prescribed hepatically metabolized drugs provide a framework adaptable to this situation.

Signals Warranting Dose Re-evaluation

Any progression in Child-Pugh class, a new diagnosis of cirrhosis by imaging or biopsy, new ascites, new encephalopathy, or a new prescription of a strong CYP3A4 inhibitor each independently trigger re-evaluation of the vardenafil dose. These are not rare scenarios in a general internal medicine or urology practice. A patient who began vardenafil at 10 mg per dose with Child-Pugh A disease and subsequently develops decompensated cirrhosis must have the prescription discontinued. Hepatology consensus statements indexed at NCBI confirm that decompensation events require re-assessment of all hepatically metabolized medications.

Vardenafil vs. Other PDE5 Inhibitors in Hepatic Impairment

Sildenafil (Viagra) and tadalafil (Cialis) share CYP3A4-dependent metabolism. Sildenafil's AUC increases approximately 84% in mild-to-moderate hepatic impairment, and tadalafil's AUC increases roughly 2-fold in Child-Pugh B patients. Vardenafil's exposure changes are broadly similar in magnitude to both comparators, meaning the class as a whole requires hepatic dosing awareness rather than vardenafil being uniquely problematic. Avanafil (Stendra) is newer and shares the same metabolic pathway with comparable label restrictions. FDA prescribing information for tadalafil details Child-Pugh B dose adjustments comparable to those for vardenafil.

The practical distinction is half-life. Tadalafil's 17.5-hour half-life versus vardenafil's 4 to 5 hours means accumulation over multiple doses is a greater concern with tadalafil in hepatically impaired patients. For men with Child-Pugh B disease who need reliable, on-demand dosing, vardenafil's shorter half-life may represent a pharmacokinetically preferable choice compared to daily-dose tadalafil, even though both require dose reduction. Comparative pharmacokinetic data for PDE5 inhibitors in special populations are reviewed in NCBI literature.

Special Populations: Cirrhosis, NAFLD, and Alcohol-Related Liver Disease

Compensated Cirrhosis (Child-Pugh A to Early B)

Men with compensated cirrhosis retain meaningful hepatic function and often have preserved libido and erectile capacity. Vardenafil at 5 mg is a reasonable starting dose in this group, with careful titration only if 5 mg proves insufficient and the patient has no cardiovascular contraindications. Portal hypertension medication regimens, particularly beta-blockers like propranolol used to prevent variceal bleeding, add an independent hypotensive risk when combined with any PDE5 inhibitor. NEJM reviews on portal hypertension management discuss co-prescribing risks in cirrhotic patients.

NAFLD Without Advanced Fibrosis

The most common liver condition in men seeking ED treatment is NAFLD without significant fibrosis. In this setting, CYP3A4 activity is mildly reduced by hepatic steatosis but usually not enough to change Child-Pugh class. Standard dosing applies, and routine LFT monitoring beyond the baseline CMP is unlikely to add clinical value. Optimizing the underlying metabolic disease (weight loss, glycemic control, lipid management) may improve both liver histology and erectile function independently. Diabetesjournals.org data link improved insulin sensitivity to partial recovery of erectile function.

Alcohol-Related Liver Disease

Acute heavy alcohol ingestion inhibits CYP3A4 transiently, raising vardenafil exposure unpredictably. Chronic alcohol-related liver disease follows the Child-Pugh classification framework directly. Physicians should ask about alcohol use at every visit in men prescribed vardenafil, both for dosing accuracy and because alcohol itself produces vasodilation and blood pressure reduction that adds to vardenafil's hemodynamic effects. NIAAA guidelines on alcohol use assessment are available through NIH.

Clinician Guidance Summary

"Patients with hepatic impairment should use vardenafil with caution. For patients with moderate hepatic impairment (Child-Pugh B), a starting dose of 5 mg is recommended; the maximum dose is 5 mg. Vardenafil has not been evaluated in patients with severe hepatic impairment (Child-Pugh C) and is therefore contraindicated in this population." This is the direct language from the FDA Levitra prescribing information.

The American Urological Association's 2018 guideline on erectile dysfunction, available through PubMed, states that PDE5 inhibitors are first-line therapy for ED in the absence of contraindications, and that clinicians should individualize dosing based on patient comorbidities including hepatic and renal function. Applying this directive in practice means Child-Pugh status assessment is not optional in men with known liver disease before any PDE5 inhibitor is written.

For patients with Child-Pugh B disease starting vardenafil 5 mg, the first follow-up should occur no later than 4 weeks after initiation to assess both hemodynamic tolerability and early response. If the 5 mg dose is tolerated but ineffective, the prescriber must weigh the clinical significance of ED against the risks of further dose escalation in the context of hepatic reserve, not simply titrate to 10 mg by default.